Clinical trials: Acromegaly
Acromegaly
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
The primary purpose of this study is to assess the effect of Debio 4126 in the maintenance of the levels of insulin-like growth factor 1 (IGF-1) ≤1x upper limit of normal (ULN) in the double-blind period (Period 1) in comparison…
- Trial name
- OXTEND™-03 (NCT06930625)
- Testing
- Debio 4126
- Where
- 74 sites in United States, Austria and 19 more
- Volunteers
- 119 people
- Sponsor
- Debiopharm International SA
Panhypopituitarism, Gigantism/Acromegaly
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
There is a variety of tumors affecting the pituitary gland in childhood; some of these tumors (eg craniopharyngioma) are included among the most common central nervous system tumors in childhood.
- Conditions
- Panhypopituitarism, Gigantism/Acromegaly, Prolactinoma, Cushing Disease
- Trial name
- NCT00001595
- Testing
- Tissue specimen collection, MRI
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Acromegaly Due to Pituitary Adenoma, Hyperglycemia
Managing Pasireotide-associated Hyperglycaemia in Acromegaly With Ketogenic Diet
Rationale: Pasireotide is a second line medical treatment for acromegaly that can add value for patients with insufficient control of disease on 1st generation SRL, or 1st generation SRL + pegvisomant.
- Conditions
- Acromegaly Due to Pituitary Adenoma, Hyperglycemia, Ketogenic Diet, Standard Care Control
- Trial name
- PasiAcroKeto (NCT07866846)
- Testing
- Ketogenic diet, Diabetes Medication
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Leiden University Medical Center
Acromegaly Due to Pituitary Adenoma, Cushing's Disease
PRESTO: A Phase III Randomised Controlled Trial of Dose-escalated Proton Beam Therapy Versus Standard of Care Radiotherapy for Functioning Pituitary Tumours
The goal of this clinical trial is to evaluate whether a higher dose of radiotherapy can lead to better outcomes for participants with functioning pituitary tumours.
- Conditions
- Acromegaly Due to Pituitary Adenoma, Cushing's Disease, Pituitary Adenoma
- Trial name
- PRESTO (NCT07813351)
- Testing
- Standard dose Intensity-Modulated Radiation Therapy (IMRT), Standard dose Proton Beam Therapy (PBT), Escalated dose Proton Beam Therapy (PBT)
- Volunteers
- 82 people
- Sponsor
- University College, London
Acromegaly
An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly
The purpose of this study is to collect long-term (up to two years) safety and effectiveness of octreotide subcutaneous depot in patients with acromegaly in the real-world setting.
- Trial name
- NCT07583563
- Testing
- Octreotide subcutaneous depot
- Where
- 6 sites in Germany, United Kingdom
- Volunteers
- 200 people
- Sponsor
- Camurus AB
Acromegaly
A Phase 1 Study to Evaluate the Relative Bioavailability of Octreotide Acetate Tablets(T25) Compared to MYCAPSSA® and The Food Effect on Pharmacokinetics Of Octreotide Acetate Tablets(T25)
The goal of this clinical trial] is to to Assess the Food Effect on the Relative Bioavailability of Orally Administrated T25 in healthy volunteers. The main questions it aims to answer are： 1.
- Trial name
- NCT07663318
- Testing
- T25-Fast, Mycapssa, T25-Fed
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Triastek (Shanghai) Limited
Acromegaly
A Study to Evaluate MAR002 for Acromegaly
Evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in participants with acromegaly
- Trial name
- NCT07641179
- Testing
- MAR002
- Where
- 3 sites in United States
- Volunteers
- 72 people
- Sponsor
- Marea Therapeutics
Acromegaly
A Clinical Trial to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Octreotide Long-acting Injection in Patients With Acromegaly
This trial is a phase II clinical trial to evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of octreotide long-acting injection in patients with acromegaly.
- Trial name
- NCT07814651
- Testing
- SYHX2008, Sandostatin LAR
- Where
- China
- Volunteers
- 78 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Acromegaly
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
The purpose of this trial is to assess the efficacy and safety of CAM2029 in patients with acromegaly. Patients will be randomized to either CAM2029 or placebo administered subcutaneously once monthly during 6 months.
- Trial name
- ACROINNOVA 1 (NCT04076462)
- Testing
- CAM2029 (octreotide subcutaneous depot)
- Where
- 63 sites in United States, Germany and 8 more
- Volunteers
- 72 people
- Sponsor
- Camurus AB
Acromegaly
ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly
The primary objective of this study is to evaluate the efficacy of 15-week treatment with ALXN2420 versus placebo for decreasing insulin-like growth factor IGF-1 levels, when administered in combination with somatostatin analog…
- Trial name
- ASTERIA (NCT07037420)
- Testing
- ALXN2420
- Where
- 6 sites in United States, Italy and 2 more
- Volunteers
- 8 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Acromegaly
A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)
A phase 2, open label, long-term extension study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with…
- Trial name
- NCT04261712
- Testing
- Paltusotine
- Where
- 22 sites in United States, Brazil and 5 more
- Volunteers
- 43 people
- Sponsor
- Crinetics Pharmaceuticals Inc.
Acromegaly
Korean Regulatory Post Marketing Surveillance for Somavert
Non-interventional observational study, to identify safety and effectiveness of Somavert during the post-marketing period based on the Korean RMP as required by the regulations of Ministry of Food and Drug Safety (MFDS)
- Trial name
- NCT05131100
- Testing
- Somavert
- Where
- South Korea
- Volunteers
- 11 people
- Sponsor
- Pfizer
Acromegaly
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly
A randomized, placebo-controlled study designed to evaluate the safety and efficacy of paltusotine (also known as CRN00808; an orally administered nonpeptide somatostatin agonist) in subjects with acromegaly previously treated…
- Trial name
- PATHFNDR-1 (NCT04837040)
- Testing
- Paltusotine
- Where
- 39 sites in United States, Argentina and 12 more
- Volunteers
- 58 people
- Sponsor
- Crinetics Pharmaceuticals Inc.
Acromegaly
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)
A randomized, placebo-controlled study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with…
- Trial name
- PATHFNDR-2 (NCT05192382)
- Testing
- Paltusotine
- Where
- 57 sites in United States, Argentina and 13 more
- Volunteers
- 111 people
- Sponsor
- Crinetics Pharmaceuticals Inc.
Acromegaly, Nonfunctioning Pituitary Adenoma
Direct Versus Video Laryngoscopy in Patients With Acromegaly
Acromegaly is associated with craniofacial skeletal changes and upper airway soft tissue hypertrophy, which may increase the risk of difficult laryngoscopy and tracheal intubation.
- Trial name
- ACRO-VL (NCT07659912)
- Volunteers
- 40 people
- Sponsor
- Muzaffer GENCER
Acromegaly
ACRODAT Prospective Evaluation Study
ACRODAT® is a new software medical device developed by a group of acromegaly experts to help practising endocrinologists assess disease activity in patients with acromegaly.
- Trial name
- NCT04349839
- Testing
- Acrodat software
- Where
- Denmark
- Volunteers
- 500 people
- Sponsor
- University of Aarhus
Diagnosed With Acromegaly, Currently in the Active Stage of the Disease
A Phase III Clinical Trial to Evaluate the Efficacy and Safety of Octreotide Long-acting Injection in Patients With Acromegaly
he purpose of this study is to evaluate the efficacy and safety of SYHX2008 injection in in patients with acromegaly.
- Trial name
- NCT07623824
- Testing
- SYHX2008, Sandostatin LAR®
- Volunteers
- 154 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Acromegaly, Gigantism
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA
The research is aimed at identifying new predisposition genes for endocrine tumours. Our focus initially is on pituitary adenomas including growth hormone-secreting tumors (somatotrophinomas) and prolactin secreting tumours…
- Conditions
- Acromegaly, Gigantism, Familial Isolated Pituitary Adenoma, FIPA
- Trial name
- NCT00461188
- Where
- 3 sites in United Kingdom
- Volunteers
- 10,000 people
- Sponsor
- Barts & The London NHS Trust
Acromegaly
Peri-operative Dynamics of the Growth Hormone Axis in Subjects With Acromegaly
Acromegaly is a rare disorder characterized by excessive production of growth hormone most often by a pituitary adenoma. A pituitary adenoma is a tumor, almost always benign or non-cancerous, that grows on the pituitary, a small…
- Trial name
- NCT00921609
- Testing
- Oral glucose tolerance test
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cedars-Sinai Medical Center
Pituitary Diseases, Pituitary Neoplasms
Long Term Outcome Study in Patients With Pituitary Disorders
To determine the outcomes of patients with different pituitary disorders whether they are managed medically, surgically or expectantly.
- Trial name
- NCT03665064
- Volunteers
- 1,500 people
- Sponsor
- University of Alberta